凯发一触即发Spike RBD蛋白详情
| 类型 |
靶点 |
表达宿主 |
标签 |
| 野生型 |
SARS-CoV-2 N protein |
Insect cell |
His |
| E.coli |
| SARS-CoV-2 S-RBD |
Insect cell |
His |
| Mammalian cell |
His/mFc |
| SARS-CoV-2 S-ECD |
Insect cell |
His/Flag |
| Mammalian cell |
| SARS-CoV-2 S1 |
Mammalian cell |
His |
| SARS-CoV-2 RBD-sc-dimerNew
|
Mammalian cell |
/ |
N Protein：核衣壳蛋白全长，序列由凯发一触即发设计并优化。
下游应用：体外诊断抗体制备，体外诊断试剂盒生产。
S-RBD：S蛋白受体结合区，序列由凯发一触即发设计，结合蛋白3D构象分析，预测更准确。
下游应用：功能检测，中和抗体制备，体外诊断试剂盒生产。
S-ECD：S蛋白膜外区全长。
下游应用：功能检测，体外诊断抗体制备。
S RBD-sc-dimer：RBD结构域中由二硫键链接二聚体。
下游应用：在MERS，SARS，COVID-19中均可构建RBD-sc-dimer结构，可用于MERS，SARS，COVID-19等疫苗制备。
| 靶点 |
应用 |
纯度 |
QC |
| S-RBD His tag |
IgM/IgG kit with Anti-His antibody |
>90% |
SDS-PAGE, WB,
ELISA binding against ACE2 |
| S-RBD mFc tag |
IgM/IgG kit with Anti-Mouse antibody |
Spike RBD蛋白，His tag
Lane M1: Protein Marker, GenScript, Cat. No. M00516
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: BSA (2.00 μg)
Lane 2: RBD Protein (Reducing condition, 2.00 μg)
Lane 3: RBD Protein (Non-reducing condition, 2.00 μg)
Lane 4: RBD Protein (Reducing condition)
Lane 5: RBD Protein (Non-reducing condition)
Primary antibody: Mouse-anti-His mAb (GenScript, Cat.No. A00186)
凯发一触即发生产的S-RBD（his tag）蛋白SDS-PAGE纯度>90%，纯度高。
采用ELISA方法检测S-RBD（his tag）蛋白与ACE2的结合活性，EC50<100ng/ml，活性好。
TCR-抗原亲和性和免疫原性筛选
个性化癌症疫苗（PCV）
个性化疫苗药效筛选
采用ELISA方法检测3个不同批次的S-RBD（his tag）蛋白与ACE2的结合活性，3个批次蛋白活性基本一致。
Spike RBD蛋白，mFc tag
Lane M1: Protein Marker, TaKaRa, Cat. No. 3452
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: Reducing condition
Lane 2: Non-reducing condition
Lane P: Mouse IgG1, Kappa (Sigma, Cat.No.M9269) as a positive
control
Primary antibody: MonoRab™ Mouse IgG (76F10), mAb, Rabbit (GenScript,
Cat.No. Cat. V90301)
凯发一触即发生产的S-RBD（mFc tag）蛋白SDS-PAGE纯度>90%，纯度高。
采用ELISA方法检测S-RBD（mFc tag）蛋白与ACE2的结合活性，EC50<100ng/ml，活性好。
Spike RBD-sc-dimer蛋白
注：Lane M: Merker
Lane 1: Reducing condition
Lane 2: Non-reducing condition
凯发一触即发生产RBD-sc-dimer，SDS-PAGE检测纯度达90%，SEC-HPLC测试纯度达97.9%，纯度高。
采用ELISA方法检测RBD-sc-dimer与ACE2蛋白结合活性，EC50低至16.8ng/ml，活性高。
Lianpan Dai, Tianyi Zheng, Kun Xu, A universal design of
betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.August,6,2020.
